References
- Hidalgo M, Álvarez R, Gallego J, et al. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol. 2017;19(6):667–681.
- Calimano-Ramirez LF, Daoud T, Jaleel A, et al. Pancreatic acinar cell carcinoma: A comprehensive review. World J Gastroenterol. 2022;28(40):5827–5844.
- Hu JX, Zhao CF, Chen WB, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298–4321.
- Amaral MJ, Oliveira RC, Donato P, Tralhão JG. Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics – A Review. Dig Dis Sci. 2023;68(7):2811–2823.
- Tacelli M, Partelli S, Arcidiacono PG. Pancreatic Neuroendocrine Neoplasms: Classification and Novel Role of Endoscopic Ultrasound in Diagnosis and Treatment Personalization. United European Gastroenterol J. 2024;13(1):34–43.
- Facing Our Risk of Cancer Empowered. Pancreatic Cancer Screening. FORCE; 2025.
- Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88-95.
- American Cancer Society. Pancreatic Neuroendocrine Tumor (pNET) Stages. ACS; 2025.
- Lellouche L, Palmieri LJ, Dermine S, et al. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Ther Adv Med Oncol. 2021;13:17588359211018539.
- Leonhardt CS, Pils D, Qadan M, et al. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Ann Surg Open. 2024;5(1):e272.
- American Cancer Society. Surgery for Pancreatic Neuroen-docrine Tumor (pNET). ACS; 2024.
- Wang M, Lozano MD, Cai G. The World Health Organization System for Reporting Pancreaticobiliary Cytopathology: Standardized Categories and Practical Approaches to Pancreatic Lesions. J Clin Transl Pathol. 2024;4(3):122-135.
- Pfister M, Probst P, Müller PC, et al. Minimally invasive versus open pancreatic surgery: meta-analysis of randomized clinical trials. BJS Open. 2023;7(2):zrad007.
- Tinguely P, Salinas CH, Raptis DA, et al. Analysis of Short-Term Outcomes in Pancreatic Surgery with Vascular Resection from a Prospective Multicenter Global Study. Ann Surg Oncol. 2025;32(12):8870-8880.
- Conroy T, Hammel P, Hebbar M, et al. Modified FOLFIRI-NOX for Resected Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406.
- Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ES-PAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024.
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703.
- Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327.
- Penev G, Grigorov E, Georgiev S. Contemporary principles and classification of peripheral nerve blocks. Meditsinski Pregled. 2022;58(1):11-20.
- Baylor College of Medicine. Palliative Care for Pancreatic Cancer.[Internet]. BCM; 2024. Available from: https://www.bcm.edu/healthcare/specialties/oncology/cancer-types/gas-trointestinal-cancers/pancreatic-cancer/palliative-care
- Viatris UK. Pancreatic cancer and PEI. [Internet]. Creon. co.uk; 2024. Available from: https://www.creon.co.uk/en-gb/hcp/enjcacy-and-tolerability/pancreatic-cancer
- American Cancer Society. Survival Rates for Pancreatic Neu-roendocrine Tumors (pNETs). [Internet[. ACS; 2025. Available from: https://www.cancer.org/cancer/types/pancreatic-neuroen-docrine-tumor/detection-diagnosis-staging/survival-rates.html